Clinical Trials featured content on bio
-
Your CRO Just Acquired Another CRO – Now What?
7/27/2013
A year ago, Wendel Barr, CEO of CRO Synteract, was frustrated. His company was profitable, he had talented personnel, Synteract was managing a wide variety of projects, and his clients were satisfied with their level of service. Despite this success, his potential to grow the business was constrained. Synteract was a U.S.-based firm with limited presence overseas. As a result, his company often found itself forced to leave money on the table, especially as its customers moved to larger, Phase 3 trials. “It became clear to us that in order to provide the range of services our customers required, we had to have more offices in Europe, beyond our office in Prague,” he says. “If you want to be a full service provider from Phase 1 to Phase 4, you have to be global.”
-
Investigator Document Portals: When Do You See The Benefits?
7/12/2013
A significant portion of the investment made in clinical trial technologies has focused on getting studies up and running more quickly.
-
The State Of SharePoint In Life Sciences
7/12/2013
The life sciences industry has been undergoing a major IT platform shift – and that shift is accelerating. Today, almost every life sciences company uses SharePoint as a general purpose collaboration and content management tool.
-
Avoid Coming Up Short On Trial Enrollment Milestones
7/2/2013
A feeling of uneasiness washes over you as you pace the sidelines and reflect upon the situation at hand during a closely contested championship game. Your team has enjoyed a great deal of success, making the playoffs in 4 out of the last 5 seasons. By Jeremy Hall, Senior Project Lead, CFS Clinical
-
Eliminate Clinical Trial Fatigue With More Effective Recruitment & Retention
6/18/2013
The average cost to develop a new drug, for most companies, is in the billions. A key contributing factor to that figure is the cost of enrolling patients. One study has shown that between 2008 and 2011, the cost for a patient in a Phase 1 trial went from $15,000 to over $20,000. For Phase 2 that cost rose from $20,000 to $35,000, and for Phase 3 it rose from $25,000 to $47,000. The smallest increase occurred in Phase 4, where costs rose from $13,000 to $17,000 (see The High Cost of Clinical Research – Who’s To Blame And What Can Be Done?). When a patient drops out of a study, the costs go even higher.
-
Resourceful Resourcing: Consolidate Your Technology Providers
6/17/2013
The tenets of clinical development for the modern life sciences industry have been unchanged for decades: we are in pursuit of developing products faster and more cost effectively while retaining efficacious, high quality data with a watchful eye on patient safety. Accomplishing this is the first objective; endeavoring to do it better than the competition is the ongoing challenge. Factoring in the constraints of a changing corporate landscape – mergers and acquisitions, downsizing or reorganizing to meet investor expectations – and a harsher regulatory environment, our industry has been forced to become more strategic and cost conscious in order to meet its goals. One strategy that has proven effective is leveraging technology innovation to streamline the very costly phases of clinical development. Companies that embrace this dynamic approach to technology resourcing will continue to emerge as leaders.
-
Five Technology Trends That Will Impact Clinical Research
6/11/2013
Zikria Syed, CEO of enterprise software company NextDocs, has seen many technology advancements in life sciences, including open standards, mobile access, tablets, and cloud computing. However, despite the cost and compliance advantages offered by many of these advancements, clinical research firms are still slow in adopting them. Research conducted by his firm shows this dynamic is about to change.
“Our sales and marketing personnel talk to clinical researchers and their CIOs every day,” he says. “I believe there is a message we are delivering to them that they are finally starting to understand: There is a technology shift going on that your peers are starting to take advantage of. If you do not embrace these changes as well, you will soon be operating at a costly productivity disadvantage.” -
Global Call Centers For Life Sciences Organizations
5/7/2013
When we think of call centers, images of the past tend to come to mind. We are reminded of the switchboard ladies in Mad Men, or outsourced client service centers where operators may not have the right linguistic or industry-specific knowledge to fully assist the customer. By Michael Smyth, General Manager, TransPerfect Life Sciences Solutions
-
The Sunshine Act - It's Finally ‘Official’
4/19/2013
So now that the long wait is over for the final rule, where do you go from here? On February 8th, 2013 the final rule of the Physician Payment Sunshine Provision (PPSP aka "Sunshine Act") was released by The Centers for Medicare and Medicaid Services (CMS). By Kevin Williams
-
5 Reasons To Synergize CTA Negotiations And Essential Document Collection
4/19/2013
The contractual and regulatory landscapes are ever-changing, increasingly complex and study timelines just keep getting shorter. By Rebecca Arch